Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. Sreter (Zagreb, Croatia). Croatian Caucasians with lung adenocarcinoma harbouring EGFR mutations with and without brain metastasis. 4262

Member's Comments

No comment yet.

Related content which might interest you: p53 gene mutations in lung cancer in Korean Source: Eur Respir J 2005; 26: Suppl. 49, 327s Year: 2005 How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Prognosis of uncommon metastasis in non-small-cell lung cancer patients with mutated EGFR Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Frequency of T790M substitution in exon 20 of EGFR gene in brain metastases in chemotherapy-naive non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 K-RAS oncogenic mutations in patients with nonsmall cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 Germline mutations in young never-smokers with lung adenocarcinoma Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001 Management of EGFR mutated nonsmall cell lung carcinoma patients Source: Eur Respir J 2015; 45: 1132-1141 Year: 2015 Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Polymorphism in GSTM1, GSTT1, p53 and CCR5 genes and lung cancer progression: relation to p53 and Ki-67 protein expression in tumors of non-small cell lung cancer patients Source: Eur Respir J 2006; 28: Suppl. 50, 810s Year: 2006 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 1550-1551 Year: 2012 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 1551 Year: 2012 Association of polymorphism of the human nm23-H1 gene (NME1) with susceptibility to and severity of non-small cell lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007